Bone Biologics prices $5.1M public offering of 3.78M units at $1.35/unit

Bone Biologics Corp

Gross proceeds $5.1M from sale of 3,777,778 units; net proceeds estimated ~$4.454M.
Each unit: 1 common share plus Series A ($1.62), B ($1.35), C ($2.16) warrants, 5-year term.
Series C warrant cashless exercise trigger: 15 days after issuance or $10M common stock volume traded.
Underwriters granted 45-day over-allotment option for up to 566,666 additional shares/warrants.
Closing expected October 12, 2022; WallachBeth Capital acting as sole book-running manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.